Reprogramming metabolism by histone methyltransferase NSD2 drives endocrine resistance via coordinated activation of pentose phosphate pathway enzymes

Junjian Wang, Zhijian Duan, Zoann Nugent, June X. Zou, Alexander D. Borowsky, Yanhong Zhang, Clifford G. Tepper, Jian Jian Li, Oliver Fiehn, Jianzhen Xu, Hsing Jien Kung, Leigh C. Murphy, Hong Wu Chen

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Metabolic reprogramming such as the aerobic glycolysis or Warburg effect is well recognized as a common feature of tumorigenesis. However, molecular mechanisms underlying metabolic alterations for tumor therapeutic resistance are poorly understood. Through gene expression profiling analysis we found that histone H3K36 methyltransferase NSD2/MMSET/WHSC1 expression was highly elevated in tamoxifen-resistant breast cancer cell lines and clinical tumors. IHC analysis indicated that NSD2 protein overexpression was associated with the disease recurrence and poor survival. Ectopic expression of NSD2 wild type, but not the methylase-defective mutant, drove endocrine resistance in multiple cell models and xenograft tumors. Mechanistically, NSD2 was recruited to and methylated H3K36me2 at the promoters of key glucose metabolic enzyme genes. Its overexpression coordinately up-regulated hexokinase 2 (HK2) and glucose-6-phosphate dehydrogenase (G6PD), two key enzymes of glycolysis and the pentose phosphate pathway (PPP), as well as TP53-induced glycolysis regulatory phosphatase TIGAR. Consequently, NSD2-driven tamoxifen-resistant cells and tumors displayed heightened PPP activity, elevated NADPH production, and reduced ROS level, without significantly altered glycolysis. These results illustrate a coordinated, epigenetic activation of key glucose metabolic enzymes in therapeutic resistance and nominate methyltransferase NSD2 as a potential therapeutic target for endocrine resistant breast cancer.

Original languageEnglish
Pages (from-to)69-79
Number of pages11
JournalCancer Letters
Volume378
Issue number2
DOIs
Publication statusPublished - Aug 10 2016
Externally publishedYes

Fingerprint

Pentose Phosphate Pathway
Glycolysis
Enzymes
Tamoxifen
Breast Neoplasms
Glucose
Neoplasms
Hexokinase
Glucosephosphate Dehydrogenase
Methyltransferases
Gene Expression Profiling
Tumor Cell Line
NADP
Phosphoric Monoester Hydrolases
Heterografts
Epigenomics
Carcinogenesis
Therapeutics
Recurrence
histone methyltransferase

Keywords

  • Histone methyltransferase
  • Metabolism
  • NSD2
  • Pentose phosphate pathway
  • Tamoxifen resistance

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Reprogramming metabolism by histone methyltransferase NSD2 drives endocrine resistance via coordinated activation of pentose phosphate pathway enzymes. / Wang, Junjian; Duan, Zhijian; Nugent, Zoann; Zou, June X.; Borowsky, Alexander D.; Zhang, Yanhong; Tepper, Clifford G.; Li, Jian Jian; Fiehn, Oliver; Xu, Jianzhen; Kung, Hsing Jien; Murphy, Leigh C.; Chen, Hong Wu.

In: Cancer Letters, Vol. 378, No. 2, 10.08.2016, p. 69-79.

Research output: Contribution to journalArticle

Wang, J, Duan, Z, Nugent, Z, Zou, JX, Borowsky, AD, Zhang, Y, Tepper, CG, Li, JJ, Fiehn, O, Xu, J, Kung, HJ, Murphy, LC & Chen, HW 2016, 'Reprogramming metabolism by histone methyltransferase NSD2 drives endocrine resistance via coordinated activation of pentose phosphate pathway enzymes', Cancer Letters, vol. 378, no. 2, pp. 69-79. https://doi.org/10.1016/j.canlet.2016.05.004
Wang, Junjian ; Duan, Zhijian ; Nugent, Zoann ; Zou, June X. ; Borowsky, Alexander D. ; Zhang, Yanhong ; Tepper, Clifford G. ; Li, Jian Jian ; Fiehn, Oliver ; Xu, Jianzhen ; Kung, Hsing Jien ; Murphy, Leigh C. ; Chen, Hong Wu. / Reprogramming metabolism by histone methyltransferase NSD2 drives endocrine resistance via coordinated activation of pentose phosphate pathway enzymes. In: Cancer Letters. 2016 ; Vol. 378, No. 2. pp. 69-79.
@article{dd3fc31f26294681837e8f90919d7730,
title = "Reprogramming metabolism by histone methyltransferase NSD2 drives endocrine resistance via coordinated activation of pentose phosphate pathway enzymes",
abstract = "Metabolic reprogramming such as the aerobic glycolysis or Warburg effect is well recognized as a common feature of tumorigenesis. However, molecular mechanisms underlying metabolic alterations for tumor therapeutic resistance are poorly understood. Through gene expression profiling analysis we found that histone H3K36 methyltransferase NSD2/MMSET/WHSC1 expression was highly elevated in tamoxifen-resistant breast cancer cell lines and clinical tumors. IHC analysis indicated that NSD2 protein overexpression was associated with the disease recurrence and poor survival. Ectopic expression of NSD2 wild type, but not the methylase-defective mutant, drove endocrine resistance in multiple cell models and xenograft tumors. Mechanistically, NSD2 was recruited to and methylated H3K36me2 at the promoters of key glucose metabolic enzyme genes. Its overexpression coordinately up-regulated hexokinase 2 (HK2) and glucose-6-phosphate dehydrogenase (G6PD), two key enzymes of glycolysis and the pentose phosphate pathway (PPP), as well as TP53-induced glycolysis regulatory phosphatase TIGAR. Consequently, NSD2-driven tamoxifen-resistant cells and tumors displayed heightened PPP activity, elevated NADPH production, and reduced ROS level, without significantly altered glycolysis. These results illustrate a coordinated, epigenetic activation of key glucose metabolic enzymes in therapeutic resistance and nominate methyltransferase NSD2 as a potential therapeutic target for endocrine resistant breast cancer.",
keywords = "Histone methyltransferase, Metabolism, NSD2, Pentose phosphate pathway, Tamoxifen resistance",
author = "Junjian Wang and Zhijian Duan and Zoann Nugent and Zou, {June X.} and Borowsky, {Alexander D.} and Yanhong Zhang and Tepper, {Clifford G.} and Li, {Jian Jian} and Oliver Fiehn and Jianzhen Xu and Kung, {Hsing Jien} and Murphy, {Leigh C.} and Chen, {Hong Wu}",
year = "2016",
month = "8",
day = "10",
doi = "10.1016/j.canlet.2016.05.004",
language = "English",
volume = "378",
pages = "69--79",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Reprogramming metabolism by histone methyltransferase NSD2 drives endocrine resistance via coordinated activation of pentose phosphate pathway enzymes

AU - Wang, Junjian

AU - Duan, Zhijian

AU - Nugent, Zoann

AU - Zou, June X.

AU - Borowsky, Alexander D.

AU - Zhang, Yanhong

AU - Tepper, Clifford G.

AU - Li, Jian Jian

AU - Fiehn, Oliver

AU - Xu, Jianzhen

AU - Kung, Hsing Jien

AU - Murphy, Leigh C.

AU - Chen, Hong Wu

PY - 2016/8/10

Y1 - 2016/8/10

N2 - Metabolic reprogramming such as the aerobic glycolysis or Warburg effect is well recognized as a common feature of tumorigenesis. However, molecular mechanisms underlying metabolic alterations for tumor therapeutic resistance are poorly understood. Through gene expression profiling analysis we found that histone H3K36 methyltransferase NSD2/MMSET/WHSC1 expression was highly elevated in tamoxifen-resistant breast cancer cell lines and clinical tumors. IHC analysis indicated that NSD2 protein overexpression was associated with the disease recurrence and poor survival. Ectopic expression of NSD2 wild type, but not the methylase-defective mutant, drove endocrine resistance in multiple cell models and xenograft tumors. Mechanistically, NSD2 was recruited to and methylated H3K36me2 at the promoters of key glucose metabolic enzyme genes. Its overexpression coordinately up-regulated hexokinase 2 (HK2) and glucose-6-phosphate dehydrogenase (G6PD), two key enzymes of glycolysis and the pentose phosphate pathway (PPP), as well as TP53-induced glycolysis regulatory phosphatase TIGAR. Consequently, NSD2-driven tamoxifen-resistant cells and tumors displayed heightened PPP activity, elevated NADPH production, and reduced ROS level, without significantly altered glycolysis. These results illustrate a coordinated, epigenetic activation of key glucose metabolic enzymes in therapeutic resistance and nominate methyltransferase NSD2 as a potential therapeutic target for endocrine resistant breast cancer.

AB - Metabolic reprogramming such as the aerobic glycolysis or Warburg effect is well recognized as a common feature of tumorigenesis. However, molecular mechanisms underlying metabolic alterations for tumor therapeutic resistance are poorly understood. Through gene expression profiling analysis we found that histone H3K36 methyltransferase NSD2/MMSET/WHSC1 expression was highly elevated in tamoxifen-resistant breast cancer cell lines and clinical tumors. IHC analysis indicated that NSD2 protein overexpression was associated with the disease recurrence and poor survival. Ectopic expression of NSD2 wild type, but not the methylase-defective mutant, drove endocrine resistance in multiple cell models and xenograft tumors. Mechanistically, NSD2 was recruited to and methylated H3K36me2 at the promoters of key glucose metabolic enzyme genes. Its overexpression coordinately up-regulated hexokinase 2 (HK2) and glucose-6-phosphate dehydrogenase (G6PD), two key enzymes of glycolysis and the pentose phosphate pathway (PPP), as well as TP53-induced glycolysis regulatory phosphatase TIGAR. Consequently, NSD2-driven tamoxifen-resistant cells and tumors displayed heightened PPP activity, elevated NADPH production, and reduced ROS level, without significantly altered glycolysis. These results illustrate a coordinated, epigenetic activation of key glucose metabolic enzymes in therapeutic resistance and nominate methyltransferase NSD2 as a potential therapeutic target for endocrine resistant breast cancer.

KW - Histone methyltransferase

KW - Metabolism

KW - NSD2

KW - Pentose phosphate pathway

KW - Tamoxifen resistance

UR - http://www.scopus.com/inward/record.url?scp=84969134879&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969134879&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2016.05.004

DO - 10.1016/j.canlet.2016.05.004

M3 - Article

VL - 378

SP - 69

EP - 79

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 2

ER -